Literature DB >> 1535226

Distribution of the ATPase inhibitor proteins of mitochondria in mammalian tissues including fibroblasts from a patient with Luft's disease.

E W Yamada1, N J Huzel.   

Abstract

The mitochondrial ATPase inhibitor proteins--the Pullman-Monroy inhibitor (PMI) and the Ca(2+)-binding protein (CaBI)--have a wide distribution, both being present in mitochondria of bovine heart and kidney, rat liver and brain, two mitochondrial populations of rabbit skeletal muscle, and mitochondria from human fibroblasts and the human breast cancer cell line T-47-D. The ratio of CaBI to PMI was highest in heart and skeletal muscle mitochondria. The subsarcolemmal fraction of skeletal muscle had 2.6-times as much CaBI as did the intermyofibrillar. The ratio of CaBI to PMI in the mitochondria of the other normal tissues and fibroblasts was close to 1. In contrast, mitochondria from T-47D cells had 1.5-times as much PMI as CaBI whilst mitochondria from fibroblasts from a patient with Luft's disease showed a virtual lack of PMI. The specific ATPase, ATP-synthetase and succinate dehydrogenase activities of the Luft's mitochondria were, however, in the normal range. The specific ATP synthetase activity of the T-47D cells was significantly higher than normal. We conclude that tissues like heart and skeletal muscle which experience wide fluctuations in intracellular Ca2+ have a greater need for CaBI. Why lack of PMI could lead to 'loose' coupling of oxidative phosphorylation in skeletal muscle of Luft's patients, but not in fibroblasts is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535226     DOI: 10.1016/0925-4439(92)90093-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  MtDNA and nuclear mutations affecting oxidative phosphorylation: correlating severity of clinical defect with extent of bioenergetic compromise.

Authors:  B H Robinson
Journal:  J Bioenerg Biomembr       Date:  1994-06       Impact factor: 2.945

2.  Role of cellular energetics in ischemia-reperfusion and ischemic preconditioning of myocardium.

Authors:  I E Hassinen; K H Vuorinen; K Ylitalo; A Ala-Rämi
Journal:  Mol Cell Biochem       Date:  1998-07       Impact factor: 3.396

Review 3.  The new role of F1Fo ATP synthase in mitochondria-mediated neurodegeneration and neuroprotection.

Authors:  Nelli Mnatsakanyan; Elizabeth Ann Jonas
Journal:  Exp Neurol       Date:  2020-07-10       Impact factor: 5.330

4.  ATPase-inhibitor proteins of brown-adipose-tissue mitochondria from warm- and cold-acclimated rats.

Authors:  E W Yamada; N J Huzel; R Bose; A L Kates; J Himms-Hagen
Journal:  Biochem J       Date:  1992-10-01       Impact factor: 3.857

Review 5.  From ATP to PTP and Back: A Dual Function for the Mitochondrial ATP Synthase.

Authors:  Paolo Bernardi; Fabio Di Lisa; Federico Fogolari; Giovanna Lippe
Journal:  Circ Res       Date:  2015-05-22       Impact factor: 17.367

Review 6.  The F1Fo-ATPase inhibitor protein IF1 in pathophysiology.

Authors:  Cristina Gatto; Martina Grandi; Giancarlo Solaini; Alessandra Baracca; Valentina Giorgio
Journal:  Front Physiol       Date:  2022-08-04       Impact factor: 4.755

7.  Molecular Regulation of the Mitochondrial F(1)F(o)-ATPsynthase: Physiological and Pathological Significance of the Inhibitory Factor 1 (IF(1)).

Authors:  Danilo Faccenda; Michelangelo Campanella
Journal:  Int J Cell Biol       Date:  2012-08-26

8.  The compound BTB06584 is an IF1 -dependent selective inhibitor of the mitochondrial F1 Fo-ATPase.

Authors:  Fabrice Ivanes; Danilo Faccenda; Jemma Gatliff; Ahmed A Ahmed; Stefania Cocco; Carol Ho Ka Cheng; Emma Allan; Claire Russell; Michael R Duchen; Michelangelo Campanella
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.